Overview

* Pediatrix Q3 revenue of about $493 mln beats analyst expectations

* Adjusted EBITDA for Q3 beats estimates, driven by favorable reimbursement factors

Outlook

* Pediatrix raises full-year 2025 Adjusted EBITDA outlook to $270 mln-$290 mln

* Company cites healthcare environment changes and uncertainties impacting outlook

Result Drivers

* REIMBURSEMENT FACTORS - CEO Mark S. Ordan attributes Q3 results to strong collection activity, higher patient acuity, and favorable payor mix

* SAME-UNIT REVENUE GROWTH - Same-unit net revenue increased by 7.6%, driven by reimbursement factors and patient service volumes

* PRACTICE DISPOSITIONS - Practice dispositions contributed to the increase in Adjusted EBITDA

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $492.87 $476.49

Revenue mln mln (7

Analysts

)

Q3 EPS $0.84

Q3 Net $71.70

Income mln

Q3 Beat $87.31 $64.26

Adjusted mln mln (6

EBITDA Analysts

)

Q3 $68.05

Income mln

from

operatio

ns

Q3 $424.82

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Pediatrix Medical Group Inc ( MD ) is $17.00, about 0.2% below its October 31 closing price of $16.97

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)